Alligator Bioscience AB 2025 AR2
The report highlights Alligator Bioscience's progress in 2025, focusing on its lead candidate, mitazalimab, which is being prepared for Phase 3 clinical trials in metastatic pancreatic cancer following positive 30-month follow-up data. The company also noted clinical advancements for HLX22, which entered a global Phase 3 trial. To support these developments and ensure financial flexibility, Alligator completed two rights issues during the year, raising approximately SEK 333 million gross. Additionally, the company successfully completed a restructuring program initiated in late 2024, significantly reducing its cost base and streamlining the organization to 11 employees by year-end.
Company: Alligator Bioscience AB
Sector: Professional & technical services
Country: Sweden
Year: 2025
Type: AR2
Pages: 114
Back to company
Alligator Bioscience AB
Annual Report
The report highlights Alligator Bioscience's progress in 2025, focusing on its lead candidate, mitazalimab, which is being prepared for Phase 3 clinical trials in metastatic pancreatic cancer following positive 30-month follow-up data. The company also noted clinical advancements for HLX22, which entered a global Phase 3 trial. To support these developments and ensure financial flexibility, Alligator completed two rights issues during the year, raising approximately SEK 333 million gross. Additionally, the company successfully completed a restructuring program initiated in late 2024, significantly reducing its cost base and streamlining the organization to 11 employees by year-end.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees